- Conditions
- Alzheimer Disease
- Interventions
- [C-11]PiB-PET/MRI
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 5,567
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Inebilizumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Austin, Texas • Seattle, Washington
- Conditions
- Nervous System Disease, Immune System Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 120 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2043
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
- Interventions
- lecanemab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 1 more
- Conditions
- Parkinson Disease
- Interventions
- Flumazenil, Placebo
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- Not listed
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 200,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Inherited Metabolic Disorders, Undiagnosed Diseases, Batten's Disease, Tay Sachs, Diabetes
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- B-cell Mediated Autoimmune Disorders
- Interventions
- Azercabtagene zapreleucel (azer-cel)
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
- Conditions
- Parkinson's Disease
- Interventions
- tDCS
- Device
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Neurofibromatosis Type 1, Neurofibroma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 20 Years to 99 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Parkinson Disease, Parkinson's Disease
- Interventions
- Ropinirole XL (formerly CR)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • San Francisco, California + 22 more
- Conditions
- Parkinson Disease, Parkinson's Disease and Parkinsonism
- Interventions
- TNM Device
- Device
- Lead sponsor
- Scion NeuroStim
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Englewood, Colorado + 18 more
- Conditions
- Multiple System Atrophy
- Interventions
- rasagiline mesylate, placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Irvine, California • La Jolla, California • Sunnyvale, California + 12 more
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
- Interventions
- AFQ056
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana
- Conditions
- Parkinson's Disease
- Interventions
- AVE8112, Placebo
- Drug
- Lead sponsor
- Michael J. Fox Foundation for Parkinson's Research
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Parkinson Disease, Accidental Falls
- Interventions
- Vitamin D3, calcium, Placebo
- Drug · Dietary Supplement · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Alzheimer Disease, Dementia
- Interventions
- The Residential Care Transition Module
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- nL-TARD-001
- Drug
- Lead sponsor
- n-Lorem Foundation
- Other
- Eligibility
- 49 Years to 49 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Renal Transplant
- Interventions
- Arm 1 Everolimus/Reduced dose tacrolimus
- Drug
- Lead sponsor
- University of Toledo Health Science Campus
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
- Interventions
- [18F]MNI-958, [18F]Florbetapir, DaTscan
- Drug
- Lead sponsor
- Molecular NeuroImaging
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimer's Disease
- Interventions
- Remternetug (IV), Remternetug (SC), Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Canoga Park, California • Carlsbad, California + 66 more
- Conditions
- Alzheimers Disease
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 22
- States / cities
- Chula Vista, California • Valencia, California • Boca Raton, Florida + 19 more
- Conditions
- Alzheimer Disease
- Interventions
- Placebo, BI 409306, Donepezil
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Sherman Oaks, California • Orlando, Florida • West Palm Beach, Florida + 7 more
- Conditions
- Anti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes
- Interventions
- Magnetic Resonance Imaging (MRI), Salpingo-oophorectomy
- Diagnostic Test · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 34 Years to 34 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida